PA Medical News about Attention Deficit Disorder with Hyperactivity

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Adjunctive Divalproex Versus Placebo for Children With ADHD and Aggression Refractory to Stimulant Monotherapy
American Journal of Psychiatry, 11/06/09

Blader JC et al. – Among children with ADHD whose chronic aggressive behavior is refractory to optimized stimulant treatment, the addition of divalproex increases the likelihood that aggression will remit. A larger trial is necessary to specify with greater precision the magnitude of benefit for adjuvant divalproex.

<< Previous
Human Follicular Lymphoma CD39+-Infiltrating T Cells Contribute...

Next >>
The Outcome of Bulimia Nervosa: Findings From One-Quarter Century...

Electrocardiographic Screening in Children With Attention-Deficit Hyperactivity Disorder
The American Journal of Cardiology, 10/22/09 Relevance Score: 94%

Comorbidity in Adults With Attention-Deficit Hyperactivity Disorder
Canadian Journal of Psychiatry, 10/20/09 Relevance Score: 94%

Variability of Response Time as a Predictor of Methylphenidate Treatment Response in Korean Children with Attention Deficit Hyperactivity Disorder
Yonsei Medical Journal, 10/29/09 Relevance Score: 93%

Adolescent Girls With Attention-Deficit/Hyperactivity and Borderline Personality Disorders
Clinical Neuropharmacology, 10/12/09 Relevance Score: 93%

Dopaminergic Haplotype as a Predictor of Spatial Inattention in Children With Attention-Deficit/Hyperactivity Disorder
Archives of General Psychiatry, 10/09/09 Relevance Score: 93%